Compare LIND & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIND | SLS |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2011 | 2007 |
| Metric | LIND | SLS |
|---|---|---|
| Price | $34.03 | $11.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $36.00 | $32.50 |
| AVG Volume (30 Days) | 851.8K | ★ 5.0M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.97 | ★ 50.00 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.49 | N/A |
| Revenue Next Year | $10.22 | N/A |
| P/E Ratio | $504.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.37 | $1.39 |
| 52 Week High | $36.97 | $15.88 |
| Indicator | LIND | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 48.42 |
| Support Level | $24.55 | $10.78 |
| Resistance Level | $34.98 | $12.62 |
| Average True Range (ATR) | 1.38 | 0.85 |
| MACD | -0.25 | 0.05 |
| Stochastic Oscillator | 16.57 | 58.58 |
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.